ID
30894
Description
Study part: PGx- Pharmacogenetic. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.
Keywords
Versions (1)
- 7/2/18 7/2/18 -
Copyright Holder
GlaxoSmithKline
Uploaded on
July 2, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
PGx- Pharmacogenetic Pazopanib Macular Degeneration MD1103367
PGx- Pharmacogenetic
- StudyEvent: ODM
Description
PGx-PHARMACOGENETIC RESEARCH WITHDRAWAL OF CONSENT (PGx Withdraw)
Alias
- UMLS CUI-1
- C1707492
Description
Consent Withdrawn
Data type
text
Alias
- UMLS CUI [1]
- C1707492
Description
sample destruction
Data type
text
Alias
- UMLS CUI [1,1]
- C0370003
- UMLS CUI [1,2]
- C1948029
Description
reason
Data type
text
Alias
- UMLS CUI [1]
- C0566251
Description
Other
Data type
text
Alias
- UMLS CUI [1]
- C0205394
Similar models
PGx- Pharmacogenetic
- StudyEvent: ODM
C1511481 (UMLS CUI-3)
C0031325 (UMLS CUI [2])
C0021430 (UMLS CUI [1,2])
C0031325 (UMLS CUI [2])
C1948029 (UMLS CUI [1,2])